Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

Journal of Dermatology

Volumn 40, Issue 1, 2013, Pages 39-42

  Takahashi, Hidetoshi ^a   Tsuji, Hitomi ^a   Ishida Yamamoto, Akemi ^a   Iizuka, Hajime ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

adalimumab; infliximab; psoriasis; Psoriasis Area and Severity Index; trough

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; DRUG ANTIBODY; INFLIXIMAB; INFLIXIMAB ANTIBODY; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MALE; PSORIASIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; AGED; BLOOD; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84872489883     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2012.01679.x     Document Type: Article

References (23)

1. Schon MP, Boehncke WH,. Psoriasis. N Engl J Med 2005; 352: 1899-1912.
2. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
3. Asahina A, Nakagawa H, Etoh T, et al,. Adalimumab M04-688 Study Group: adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
4. Torii H, Nakagawa H,. Japanese Infliximab Study Investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol 2011; 38: 321-334.
5. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J,. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumor necrosis factor-alpha antibodies. Scand J Gastroenterol 2009; 44: 774-781.
6. Lecluse LL, Driessen RJ, Spuls PI, et al,. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-132.
7. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608.
8. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-1254.
9. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
10. Casteele NV, Ballet V, Assche GV, Rutgeerts P, Vermeire S, Gils A,. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012; 61: 321.
11. Karmiris K, Paintaud G, Noman M, et al,. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-1640.
12. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al,. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-1468.
13. Klotz U, Teml A, Schwab M,. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46: 645-660.
14. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth AM,. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310-318.
15. Ducourau E, Mulleman D, Paintaud G, et al,. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011; 13: 105-111.
16. Pariente B, de Chambrun GP, Krzysiek R, et al,. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011; 18: 199-206.
17. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al,. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphism. Arthritis Rheum 2009; 60: 2541-2542.
18. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al,. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentration in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-926.
19. Vermeire S, Norman M, van Assche G, Baert F, D'Haens G, Rutgeerts P,. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-1231.
20. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ,. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010; 12: 217.
21. Maini RN, Breedveild FC, Kalden JR, et al,. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563.
22. Radstake TR, Svenson M, Eijsbouts AM, et al,. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-1745.
23. Cassinotti A, Travis S,. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-1275.